Search Results for "Contraceptives"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Contraceptives. Results 101 to 110 of 261 total matches.
Uterine Artery Embolization for Fibroids
The Medical Letter on Drugs and Therapeutics • Apr 11, 2005 (Issue 1206)
contraceptives and GnRH agonists such as
leuprolide (Lupron, and others) have been used to
relieve symptoms.
3 ...
Uterine artery embolization (UAE) is an increasingly used alternative to surgery for treatment of uterine fibroids.
ThermaClear for Acne
The Medical Letter on Drugs and Therapeutics • Jun 18, 2007 (Issue 1263)
isotretinoin (Accutane, and
others) is used to treat severe recalcitrant nodular
acne. Oral contraceptives ...
The FDA has approved ThermaClear (Therative), a battery-powered, handheld device, to treat individual acne lesions with heat. ThermaClear is indicated only for use on mild to moderate inflammatory acne, not severe nodular or severe cystic acne, and it is not meant to be used on blackheads and whiteheads. Two similar devices are already on the market: Zeno, another handheld device that delivers heat to acne lesions, and the Radiancy Clear Touch Lite Acne Clearance System, a larger heat-delivery device.
Lesinurad (Zurampic) for Gout-Associated Hyperuricemia
The Medical Letter on Drugs and Therapeutics • Nov 21, 2016 (Issue 1508)
decrease the efficacy of
hormonal contraceptives; use of a nonhormonal
contraceptive is recommended while ...
The FDA has approved lesinurad (Zurampic –
Ironwood), a uric acid transporter 1 (URAT1)
inhibitor, for adjunctive treatment of gout-associated
hyperuricemia in patients whose serum uric acid
levels fail to reach goal with xanthine oxidase
inhibitor monotherapy.
In Brief: Technivie for HCV Genotype 4 Infection (online only)
The Medical Letter on Drugs and Therapeutics • Nov 23, 2015 (Issue 1482)
ombitasvir oral contraceptives paritaprevir Viekira Pak Tehnivie sofosbuvir simvastatin Ritonavir Ribavirin ...
The FDA has approved Technivie (Abbvie), a fixed-dose combination of the direct-acting antiviral agents ombitasvir and paritaprevir and the pharmacokinetic enhancer ritonavir, for oral treatment of chronic hepatitis C virus (HCV) genotype 4 infection in patients without cirrhosis. It is indicated for use in combination with ribavirin. Ombitasvir/paritaprevir/ritonavir copackaged with dasabuvir, an HCV RNA polymerase inhibitor that has little activity against HCV genotype 4, is approved as Viekira Pak for treatment of HCV genotype 1 infection.1HCV genotype 4 is uncommon in the US and Canada. It...
Mifepristone (Mifeprex) Label Changes
The Medical Letter on Drugs and Therapeutics • Apr 25, 2016 (Issue 1493)
or vaginal misoprostol for abortion through 56 days of last
menstrual period. Contraception 2005; 72:328 ...
The FDA has approved several significant changes in
the labeling of mifepristone (Mifeprex – Danco), an oral
antiprogestin that has been used in the US for more than
15 years for termination of intrauterine pregnancy. It
has generally been used with the prostaglandin analog
misoprostol (Cytotec, and generics).
Capmatinib (Tabrecta) for NSCLC (online only)
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023 (Issue 1674)
effective contraception during
treatment with capmatinib and for one week after
the last dose ...
The FDA has granted regular approval to the oral
kinase inhibitor capmatinib (Tabrecta – Novartis) for
treatment of metastatic non-small cell lung cancer
(NSCLC) in adults whose tumors have a mutation that
leads to mesenchymal-epithelial transition (MET)
exon 14 skipping. MET exon 14 skipping mutations
occur in 3-4% of NSCLC cases. The drug received
accelerated approval for the same indication in 2020
based on initial overall response rates and duration
of response.
Med Lett Drugs Ther. 2023 Apr 17;65(1674):e65-6 doi:10.58347/tml.2023.1674d | Show Introduction Hide Introduction
In Brief: A New Indication for Pemigatinib (Pemazyre) (online only)
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023 (Issue 1674)
should use effective contraception
during treatment with pemigatinib and for 1 week
after the last dose ...
The oral kinase inhibitor pemigatinib (Pemazyre –
Incyte) has been approved by the FDA for treatment
of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with fibroblast growth
factor receptor 1 (FGFR1) rearrangements. It is the
first targeted therapy to be approved in the US for this
indication. The drug received accelerated approval
from the FDA in 2020 for treatment of adults with
previously treated, unresectable, locally advanced or
metastatic cholangiocarcinoma with FGFR2 fusions
or other rearrangements.
Med Lett Drugs Ther. 2023 Apr 17;65(1674):e71-2 doi:10.58347/tml.2023.1674g | Show Introduction Hide Introduction
Eflornithine (Iwilfin) for High-Risk Neuroblastoma (online only)
The Medical Letter on Drugs and Therapeutics • May 13, 2024 (Issue 1702)
with reproductive potential should use effective
contraception during treatment with eflornithine and
for 1 week ...
Eflornithine (Iwilfin – US WorldMeds), an oral ornithine
decarboxylase inhibitor, has been approved by the
FDA to reduce the risk of relapse in children and with
high-risk neuroblastoma who had at least a partial
response to prior multiagent, multimodality therapy,
including anti-GD2 immunotherapy. About 40-50%
of neuroblastoma cases are classified as high-risk
and they account for ~15% of all pediatric cancer
deaths. Eflornithine is the first drug to be approved
to reduce the risk of relapse in children with high-risk
neuroblastoma. Eflornithine was previously available
in the US...
Med Lett Drugs Ther. 2024 May 13;66(1702):e81-2 doi:10.58347/tml.2024.1702f | Show Introduction Hide Introduction
In Brief: Exenatide (Byetta) for Weight Loss
The Medical Letter on Drugs and Therapeutics • Mar 13, 2006 (Issue 1230)
of absorption of other drugs
such as antibiotics and oral contraceptives; oral drugs
should be taken at least ...
Patients may be asking about reports in the lay press that exenatide (Byetta - Med Lett Drugs Ther 2005; 47:45), a synthetic peptide that stimulates release of insulin from pancreatic beta cells, has been used by diabetics and non-diabetics to lose weight. Approved by the FDA to improve glycemic control in patients with type 2 diabetes not controlled by metformin, a sulfonylurea or both, it is given by subcutaneous injection before the morning and evening meals. In clinical trials, some diabetic patients treated with the drug lost weight. No data are available on use in non-diabetics....
Mifepristone (Korlym) for Cushing's Syndrome
The Medical Letter on Drugs and Therapeutics • Jun 11, 2012 (Issue 1392)
is contraindicated
for use during pregnancy.Women of childbearing
age should use contraception during
treatment ...
The FDA has approved the antiprogestin mifepristone
(Korlym – Corcept Therapeutics) for control of hyperglycemia
secondary to hypercortisolism in adults with
endogenous Cushing’s syndrome who have type 2 diabetes/
glucose intolerance and have not responded to,
or are not candidates for, surgery. Formerly known as
RU 486, mifepristone is also available in a lower
strength as Mifeprex for use in terminating an early
intrauterine pregnancy.